Pfizer Corporation

Abbvie Biotechnology Ltd

John Lance Perez

Kathrin Ute Jansen

Annaliesa Sybil Anderson

Thomas Richard Jones

Shannon Lea Harris

Gary Warren Zlotnick

Leah Diane Fletcher

John Erwin Farley

Lakshmi Khandke

Paul A Liberator

Judith Absalon

Johannes Frederik Beeslaar

David Cooper

Rasappa Gounder Arumugham

Bounthon Loun

Lynn Marie Phelan

Jose Miguel Aste-Amezaga

Isis Kanevsky

Jeffrey Kent

Hartmut Kupper

Edward Keystone

Arthur Kavanaugh

Mary A Cifaldi

Gerd R Burmester

Philip Mease

Daniel J Lovell

Jason Douglas Maguire

Cuiwen Tan

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 &#x3bc;g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 &#x3bc;g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

[object Object]

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of rheumatoid arthritis in a subject.

Methods for determining efficacy of TNF-&#x3b1; inhibitors for treatment of rheumatoid arthritis

Growing community of inventors

Doylestown, PA, United States of America

John Lance Perez